Audited Financial Statements' Announcement for The Year

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
101
Audited Financial Statements' Announcement for The Year Ended 31 December 2016

EASTPHARMA LTD.

  London, 10 March 2017 - EastPharma (EAST LI)  announces it will be releasing its audited financial statements for the year ended 31 December 2016  and a review of its main subsidiary DEVA Holding's audited financial statements for the related period.

Management comment on the financial performance of EastPharma is provided in the attachment, and a presentation of the results will be available on the EastPharma website www.eastpharma.com on 13 March 2017.

A conference call to review the financial performance for the year ended 31 December 2016 will be hosted by the management of EastPharma at 12:00-noon London time on 13 March 2017 (08:00am New York time / 01:00-pm Zurich time / 03:00pm Istanbul time). The dial-in details are provided below.

Conference call:

Dial-in Number (UK): + 44 (0)20 7162 0077 Dial-in Number (US): + 1 646 851 2407 Dial-in Number (Switzerland): + 41 (0)434 5692 61 Dial-in Number (Germany): + 49 (0)695 8999 0507

Conference ID:  961504

For further information, please contact: Investor Relations: email: ir@eastpharma.com

MANAGEMENT COMMENTS ON EASTPHARMA's FINANCIAL PERFORMANCE IN 12M 2016 (IFRS):

According to IFRS results, revenue in 12M 2016 was USD 224.9mn, up 7.2% from the same period in 2015 (USD 209.9mn). In Turkish Lira terms, revenue increased by 19.1% in the same period (Net sales in 12M 2016 were TRY 676.0mn vs TRY 567.5mn net sales in 12M 2015).

The average US Dollar exchange rate strengthened by 11.0% against the Turkish Lira to 3.0181 in 12M 2016, which compares with an average rate of 2.7191 in 12M 2015. The USD/TRY exchange rate was 3.5192 on 31 December 2016, while it was 2.9076 on 31 December 2015, which corresponds to an increase of 21.0%.

EastPharma's sales increase was mainly achieved by both increased volumes at human pharma businesses and the price increase which was effective as of 22 February 2016. In 12M 2016 versus 12M 2015, Human Pharma revenues in US dollar terms increased by 7.1% (from USD 195.3mn to USD 209.2mn). Veterinary products revenues increased by 8.6% (from USD 11.77mn to USD 12.78mn)

Deva's Capital Markets Board (CMB) results show revenue in 12M 2016 was TRY 688.5mn, up 19.4% from the same period in 2015 (TRY 576.4mn). In 12M 2016 versus 12M 2015, Human Pharma revenue increased by 19.5% (from TRY 536.8mn to TRY 641.3mn). Veterinary business revenue increased by 20.4% compared to the 12M 2015 (from TRY 31.89mn to TRY 38.41mn).

EastPharma's gross profit in 12M 2016 was USD 102.0mn, up from USD 92.4mn in 12M 2015. The gross profit margin in 12M 2016 was 45% vs 44% in 12M 2015.

EBITDA in 12M 2016 was USD 55.8mn vs USD 46.5mn in 12M 2015 representing an EBITDA margin of 24.8% vs 22.1% in 12M 2015.

Operating expenses in 12M 2016 increased by 1.1%, from USD 62.5mn to USD 63.2mn. The ratio of operating expenses to revenues decreased to 28.1% from 29.8% compared to 12M 2015. Sales and marketing expenses in 12M 2016 were 14.3% of revenues; general administrative expenses were 12.0% of revenues; research and development expenses were 1.8% of revenues. These expenses were 15.9%, 11.6% and 2.3% in 12M 2015, respectively.

Finance cost decreased by USD 1.57mn in 12M 2016 compared to the same period of 2015; from USD 35.27mn to USD 33.70mn. Foreign exchange gain/losses on borrowings decreased by USD 0.4mn, amortization of discount on receivables decreased by USD 1.15mn, other finance expenses decreased by USD 0.25mn and on the other hand interest on borrowings and bond interests and expenses increased by USD 0.23mn. Average TRY interest rate increased to 11.9% in 12M 2016 from 11.3% in 12M 2015.

Receivable days at 31 December 2016 were 109 days, compared to 120 days as at 31 December 2015.

Philipp Haas, EastPharma's Chairman and CEO, stated;

'The headwinds in the market, which started in mid 2016, continued throughout the second half of the year, the most important ones being restrictions on reimbursement of high volume products, increased competition in the domestic market and a deterioration of the value of the Turkish Lira. Despite these margin pressures, we were still able to hold and even slightly increase our gross profit margin by executing further cost saving programs, introducing new products as well as through a strong increase of sales in volume terms.

While the weak Turkish Lira was very detrimental for our gross profit margin, there was one positive effect, which was a marked decrease of our debt in US Dollar term by 26.6%, enabled by our strategy to keep all our debt in Turkish Lira terms.

For 2017, we estimate that the same headwinds will continue, however, our company is well positioned to confront the upcoming challenges, especially through the introduction of new products, which is a result of many years of heavy investments in R&D and which will further strengthen us in the key areas of our activities.'

EastPharma Ltd - a company active in the manufacturing and marketing of pharmaceutical products in Turkey and in other regional markets; for further information please visit www.eastpharma.com

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...44dcf38643

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...f045c10027

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 205

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 286

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 327

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 207

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 221

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 330

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 299

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 287

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 264

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading

Top 5 Most Recently Viewed Articles

Elis Capital Structure Overview and Voting Rights Update

Updated Category News Views 292

Elis Capital Structure Overview Elis, a prominent player in the services sector, is committed to providing transparency regarding its capital structure. As of the recent assessment, the company detailed the number of shares that constitute its capital along with the total number of voting rights. Share Capital and Voting Rights According to French legal requirements,...

Continue Reading
A. Walker & Company Secures $50 Million for Housing Projects

Updated Category News Views 244

A. Walker & Company Secures Major Capital Commitments A. Walker & Co. recently secured a significant capital commitment totaling up to $75 million, including an initial $50 million specifically set aside for affordable housing development. This funding is a critical step towards increasing the availability of multifamily housing that can effectively serve the needs of...

Continue Reading
ClorDiSys Enhances Sterilization Capabilities with Expansion

Updated Category News Views 228

ClorDiSys Expands Sterilization Operations ClorDiSys Solutions, LLC has announced a significant expansion in its sterilization facilities, designed to address the growing demand for its chlorine dioxide-based sterilization services. This expansion includes the addition of new chambers, which will effectively double the company’s processing capacity. With the new...

Continue Reading
Star Equity's KBS Builders Secures Major Contracts Worth $5.2M

Updated Category News Views 173

KBS Builders Secures Significant Commercial Contracts Star Equity Holdings, Inc. is excited to announce that its subsidiary, KBS Builders, has successfully signed two major contracts worth a total of $5.2 million. These contracts focus on the manufacturing of housing units, promising to contribute positively not only to KBS's growth but also to addressing the ongoing...

Continue Reading
Navigating the Startup Jungle: Break Free from Traps

Updated Category News Views 158

Understanding the Existing Market Trap A fresh approach from the creators of Play Bigger reveals the hidden costs startups face. The new book titled The Existing Market Trap: A Primer presents a timely exploration into why many startups struggle to gain traction. Co-authors Al Ramadan, Christopher Lochhead, alongside new contributors Jason Wellcome and Mary Gr

Continue Reading